{"id":"W3087498123","doi":"10.1016/j.cllc.2020.09.007","title":"Nanoparticle Albumin-bound Paclitaxel Plus Carboplatin Induction Followed by Nanoparticle Albumin-bound Paclitaxel Maintenance in Squamous Non–Small-cell Lung Cancer (ABOUND.sqm): A Phase III Randomized Clinical Trial","year":2020,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Nanoparticle-Based Drug Delivery","field":"Materials Science","cited_by":13,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Guardant Health; Roche Diagnostics; Bristol-Myers Squibb Canada; Genentech; AstraZeneca; Fundación Agencia Aragonesa para la Investigación y el Desarrollo; C17 Children's Cancer and Blood Disorders; Astellas Pharma; University of Texas Southwestern Medical Center; Merck Sharp and Dohme; Takeda Pharmaceuticals U.S.A.; Simmons College; AbbVie; University of Arizona Cancer Center; Alexion Pharmaceuticals; PharmaMar; Novartis; Celgene; Boehringer Ingelheim; Ariad Pharmaceuticals; Roche; Merck; Pfizer; Bristol-Myers Squibb; Eli Lilly and Company; Sarah Cannon Research Institute","keywords":"Medicine; Paclitaxel; Hazard ratio; Internal medicine; Clinical endpoint; Lung cancer; Carboplatin; Interim analysis; Gastroenterology; Randomized controlled trial; Progression-free survival; Confidence interval; Oncology; Cancer; Surgery; Chemotherapy","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.01032628,0.001143977,0.003861202,0.0001641165,0.0005382476,0.0005985473,0.001282995,0.0009028262,0.001272938],"category_scores_gemma":[0.006244945,0.001047433,0.001264409,0.001429745,0.001902605,0.0009889953,0.0005400337,0.001639583,0.0002468659],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001260879,"about_ca_system_score_gemma":0.002713383,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003746695,"about_ca_topic_score_gemma":0.00196731,"domain_scores_codex":[0.982868,0.003760138,0.006577174,0.002993837,0.00136598,0.002434923],"domain_scores_gemma":[0.988386,0.005891793,0.002051837,0.001439899,0.0005294488,0.001700963],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.4281708,0.003581892,0.007829233,0.0002990484,0.0002653514,0.00021915,0.001822778,0.0009803529,0.5201892,0.00006959328,0.03492327,0.00164932],"study_design_scores_gemma":[0.7368859,0.001780152,0.0002422869,0.0003780266,0.00134929,0.000006016799,0.0005222571,0.09193879,0.1636493,0.0001127479,0.001486106,0.001649169],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9733868,0.005627891,0.0004429005,0.005303412,0.007524421,0.006818408,0.0003939878,0.0003619558,0.000140228],"genre_scores_gemma":[0.9881784,0.0006954492,0.0003932457,0.0042818,0.002387361,0.002734818,0.00004534241,0.0002095303,0.001074001],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3565399,"threshold_uncertainty_score":0.99964,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04164487511171669,"score_gpt":0.3698253989518835,"score_spread":0.3281805238401668,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}